Literature DB >> 1797830

Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.

J de Jong1, W S Guérand, P R Schoofs, A Bast, W J van der Vijgh.   

Abstract

Anthracyclines are very effective against soft tissue sarcomas, with cardiotoxicity being an important side effect after repeated administration. To estimate the relative cardiotoxicity of various anthracyclines and their metabolites, we developed an isolated mouse left atrium model. To relate an effect of doxorubicin, 4'-epidoxorubicin and their four main metabolites (doxorubicinol, epidoxorubicinol and the aglycons 7-deoxydoxorubicinon and 7-deoxydoxorubicinolon) to concentrations in the tissue instead of the incubation bath, a method of quantifying the anthracyclines in small tissue samples was developed. Atria were homogenized by sonication followed by extraction of the anthracyclines with methanol. The extract was directly analyzed by high-performance liquid chromatography with fluorescence detection. Recoveries for the six compounds tested ranged from 67.5% for 4'-epidoxorubicin to 100.6% for 7-deoxydoxorubinol aglycon with coefficients of variation of 2-3% at two spiked concentrations (0.1 and 1 nmol/mg of tissue). The calibration plots were linear (r2 greater than 0.996) over the concentration range tested (0.05-1 nmol/mg wet weight). The limits of detection (4-10 pmol/mg of tissue) were low enough to allow the determination of the anthracyclines at all relevant tissue concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797830     DOI: 10.1016/0378-4347(91)80218-2

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

2.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

3.  Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

Authors:  Adolfo Quiñones-Lombraña; Daniel Ferguson; Rachael Hageman Blair; James L Kalabus; Almedina Redzematovic; Javier G Blanco
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

4.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  Anticancer Drugs       Date:  2013-10       Impact factor: 2.248

6.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

7.  The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

Authors:  P H Houba; E Boven; C A Erkelens; R G Leenders; J W Scheeren; H M Pinedo; H J Haisma
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

8.  A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.

Authors:  P H Houba; E Boven; I H van der Meulen-Muileman; R G Leenders; J W Scheeren; H M Pinedo; H J Haisma
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.